USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME AND CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE

The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 25. Jan. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

LI CHUNLEI [VerfasserIn]
XIA XUEFANG [VerfasserIn]
LI YANHUI [VerfasserIn]
AN NA [VerfasserIn]
DU YANLING [VerfasserIn]
LI TONG [VerfasserIn]
WANG SHIXIA [VerfasserIn]
JIA RUNLU [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-01-25, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09

Patentnummer:

US2024024257

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA019180438